Drug

SPC-14

Targeting Alzheimer’s

Market Opportunity

Alzheimer’s Disease

  • 6.5 million Americans suffer from Alzheimer’s and related diseases
  • ~1 in 9 Americans 65+ have Alzheimer’s
  • U.S. market for relevant drugs expected to reach $5 billion by 2027

Technology

  • Licensed from Columbia University
  • SPC-14 is a novel drug combining two approved therapeutics
  • SPC-14 targets NDMARS and 5HT4Rs to treat cognitive and europychiatric symptoms in Alzheimers

Regulatory Pathway & Results

  • 505(b)(2) Pathway
  • Preclinical testing and proof-of-concept being lead by inventor Dr. Christine Denny of Columbia University
  • SPC-14 has shown reduced hyponeophagia in animal studies 
  • SPC-14 may reduce behavioral despair
  • Silo has licensed technology with Columbia and has recently entered into a scientific research agreement with Dr. Denny’s lab

Get more information on Silo Pharma. Sign up for email alerts online.